BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year
- Nov 4, 2025
- 1 min read
CEO Jordi Fàbrega and CSO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.
Coverage brought to you by










.png)

